Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

United Therapeutics gets rights to use Ascendis Pharma's TransCon technology; terminated

Executive Summary

United Therapeutics Corp. (hypertension, cancer, and infectious disease treatments) has licensed exclusive rights to use Ascendis Pharma AS’s (improves existing drugs with its linker platform) TransCon technology to deliver Remodulin (treprostinil) for pulmonary arterial hypertension (PAH).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register